Full Text View
Tabular View
No Study Results Posted
Related Studies
Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-Daily or Twice-Daily Coreg
This study is ongoing, but not recruiting participants.
First Received: January 5, 2006   Last Updated: February 6, 2006   History of Changes
Sponsor: Cardiovascular Clinical Studies
Collaborator: GlaxoSmithKline
Information provided by: Cardiovascular Clinical Studies
ClinicalTrials.gov Identifier: NCT00272805
  Purpose

The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release carvedilol (Coreg) twice a day.


Condition Intervention Phase
Chronic Heart Failure
Drug: carvedilol
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment
Official Title: Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR Vs Twice-Daily COREG Immediate Release(IR)on Measures of Compliance and Quality of Life in Patients With Heart Failure and Left Ventricular Systolic Dysfunction

Resource links provided by NLM:


Further study details as provided by Cardiovascular Clinical Studies:

Primary Outcome Measures:
  • Dosing compliance: pill taking total taken vs number prescribed

Secondary Outcome Measures:
  • quality of life

Estimated Enrollment: 400
Study Start Date: October 2005
Detailed Description:

Study Further Study Details:

Primary outcome: pill-taking compliance (total doses taken versus total doses prescribed)

Expected Total Enrollment: 400 subjects at 56 study sites in the U.S.

Study Start: October 2005

This is a 5-month double-blind treatment study of male and female subjects with stable mild-to-severe chronic heart failure and with left ventricular dysfunction with symptoms of heart failure.

Eligibility:

Must be stable on treatment with Coreg IR at a standard dose: 6.25, 12.5, 25 mg twice a day.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to read English
  • Stable symptoms of mild to severe heart failure
  • Stable medical regimen for heart failure
  • On a stable dose of Coreg for at least 2 months
  • LVEF ≤40% within the previous 24 months

Exclusion Criteria:

  • Uncorrected obstructive or regurgitant valve disease
  • Complex congenital heart disease
  • Recent ICD or pacemaker placement
  • Recent coronary artery bypass surgery or stroke
  • Candidate for heart transplanct within 5 months of study start
  • Present or planned use of MAO inhibitors, alfpha-blockers, combined alpha-beta blockers, any Class I/II anti-arrythmnic agents, (amiodarone may be used if ≤ 200mg/day). Use of intravenous vasodilator/inotropic agents.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00272805

  Hide Study Locations
Locations
United States, Alabama
The Heart Group
Mobile, Alabama, United States, 36608
United States, Arizona
Radiant Research
Sierra Vista, Arizona, United States, 85635
United States, California
Northern California Medical Associates
Santa Rosa, California, United States, 95403
San Diego Cardiac Center
San Diego, California, United States, 34203
Radiant Research
Santa Rosa, California, United States, 95405
Cardiology Consultants of Orange County
Anaheim, California, United States, 92801
Access Clinical Trials
Beverly Hills, California, United States, 90210
Cardiovascular Consultants Medical Group
Walnut Creek, California, United States, 94598
Cardiovascular Consultants Medical Group
Oakland, California, United States, 94609
United States, Colorado
Heart Center of the Rockies
Fort Collins, Colorado, United States, 80528
United States, Connecticut
St. Francis Hospital and Medical Center
Hartford, Connecticut, United States, 06105
United States, Florida
NextPhase Clinical Trials
Miami, Florida, United States, 33126
Charlotte Heart Group Research Center
Port Charlotte, Florida, United States, 33952
The Heart and Vascular Institute of Florida
St. Petersburg, Florida, United States, 33701
United States, Georgia
CVMS Research Institute of Augusta
Augusta, Georgia, United States, 30901
Georgia Heart Specialists
Covington, Georgia, United States, 30014
Cardiac Disease Specialists
Atlanta, Georgia, United States, 30309
United States, Idaho
Idaho Cardiology Associates
Boise, Idaho, United States, 83704
United States, Illinois
North Shore Cardiologists
Bannockburn, Illinois, United States, 60015
Illinois Heart and Lung Research Center
Normal, Illinois, United States, 61761
Midwest Heart Foundation
Lombard, Illinois, United States, 60148
United States, Indiana
The Care Group
Indianapolis, Indiana, United States, 46260
United States, Louisiana
Clinical Trials Management
Metairie, Louisiana, United States, 70006
United States, Maine
Cardiovascular Consultants of Maine
Scarborough, Maine, United States, 04074
Androscoggin Cardiology Associates-Research
Auburn, Maine, United States, 04210
Maine Cardiology Associates
S. Portland, Maine, United States, 04106
United States, Massachusetts
Pentucket Medical Associates
Haverhill, Massachusetts, United States, 01830
Primary Care Cardiology Research
Ayer, Massachusetts, United States, 01432
Lahey Clinic Cardiology
Burlington, Massachusetts, United States, 01805
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, Nebraska
Bryan LGH Heart Institute
Lincoln, Nebraska, United States, 68516
United States, Nevada
Lovelace Scientific Resources
Las Vegas, Nevada, United States, 89128
United States, New Jersey
Associated Cardiovascular Consultants
Cherry Hill, New Jersey, United States, 08034
United States, New Mexico
University of New Mexico Health Science Center
Albuquerque, New Mexico, United States, 87131
United States, New York
South Bay Cardiovascular Associates
West Islip, New York, United States, 11795
Cardiovascular Medical Associates
Garden City, New York, United States, 11530
New York University Medical School
New York, New York, United States, 10016
MidValley Cardiology
Kingston, New York, United States, 12401
Albany Associates in Cardiology
Albany, New York, United States, 12205
United States, North Carolina
Alamance Regional Medical Center
Burlington, North Carolina, United States, 27215
United States, Ohio
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States, 45219
The Dayton Heart Center
Dayton, Ohio, United States, 45414
New Horizons Clinical Research
Cincinnati, Ohio, United States, 45242
Akron General Medical Center
Akron, Ohio, United States, 44307
North Ohio Research Ltd.
Sandusky, Ohio, United States, 44870
North Ohio Research Ltd.
Lorain, Ohio, United States, 44503
United States, Oklahoma
Blue Stem Cardiology
Bartlesville, Oklahoma, United States, 74006
United States, Oregon
Cardiovascular Consultants of Oregon
Corvallis, Oregon, United States, 97330
Oregon Medical Group Clinical Research
Eugene, Oregon, United States, 97401
United States, Pennsylvania
Guthrie Clinic Ltd.
Sayre, Pennsylvania, United States, 18840
United States, Rhode Island
Rhode Island Heart Failure Center
Providence, Rhode Island, United States, 02903
United States, Texas
DCOL Center for Clinical Research
Longview, Texas, United States, 75605
United States, Utah
LDS Hospital Cardiovascular Research
Salt Lake City, Utah, United States, 84143
United States, Wisconsin
Arrythmia Center for Southern Wisconsin
Elkhorn, Wisconsin, United States, 53121
Sponsors and Collaborators
Cardiovascular Clinical Studies
GlaxoSmithKline
Investigators
Principal Investigator: James E. Udelson, M.D. Cardiovascular Clinical Studies, Inc.
  More Information

No publications provided by Cardiovascular Clinical Studies

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Study ID Numbers: CCS 2005-001, CASPER
Study First Received: January 5, 2006
Last Updated: February 6, 2006
ClinicalTrials.gov Identifier: NCT00272805     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Cardiovascular Clinical Studies:
chronic heart failure
left ventricular systolic dysfunction

Additional relevant MeSH terms:
Vasodilator Agents
Heart Failure
Neurotransmitter Agents
Heart Diseases
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic alpha-Antagonists
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Therapeutic Uses
Adrenergic beta-Antagonists
Cardiovascular Diseases
Adrenergic Antagonists
Carvedilol

ClinicalTrials.gov processed this record on November 27, 2009